Skip to content

Study · Observational study · n = 15 · 2020

6 results

Histrelin Implantation and Growth Outcomes in Children With Congenital Adrenal Hyperplasia: An Institutional Experience.

Swendiman RA, Coons BE, Alter CA, Bamba V, Nance ML, Vogiatzi MG

Journal of the Endocrine Society13 Nov 2019

PMID32104750 (opens in a new tab)PMCIDPMC7035208 (opens in a new tab)DOI10.1210/jendso/bvz004 (opens in a new tab)PepBankPUB-32104750
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In children with CAH, BA/CA decreased from 1.57 ± 0.4 to 1.25 ± 0.25 during histrelin treatment (P < .01).

    In plain wordsIn children with CAH, bone age relative to chronological age decreased during histrelin treatment compared with baseline.

    Peptide
    Histrelin
    Outcome
    DecreaseBone age to chronologic age ratio
    Study

    n = 15

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · median 3 years (range 2-5)As given in this study (human).

    Measurements

    Bone age to chronologic age ratio at baseline
    1.57 ratio
    children with CAH before histrelin, ± 0.4
    Bone age to chronologic age ratio after treatment
    1.25 ratio
    children with CAH on histrelin, ± 0.25

    Source sentences

    Summary
    Bone age (BA) to chronologic age (CA) decreased from 1.57 ± 0.4 to 1.25 ± 0.25 (P < .01), while predicted adult height (PAH) increased by 7.1 ± 6.6 cm (P < .01).
    3 context sentences
    Summary · context
    Fifteen children with CAH were treated with histrelin for a median of 3 years (range 2-5; age at first implantation 7.7 ± 1.5 years).
    Summary · context
    Retrospective cohort analysis of all patients (age ≤ 20) at our institution who underwent histrelin implantation between 2008 and 2017.
    Summary · context
    Treated patients with CAH (classic and nonclassic forms of 21OHD) were identified and their growth data analyzed.
  2. 02HumanObservational studyEfficacy outcome

    In children with CAH, predicted adult height increased by 7.1 ± 6.6 cm during histrelin treatment (P < .01).

    In plain wordsIn children with CAH, predicted adult height increased during histrelin treatment compared with baseline.

    Peptide
    Histrelin
    Outcome
    IncreasePredicted adult height
    Study

    n = 15

    Outcome group
    Linear growth · Musculoskeletal
    Studied dose
    Dose not stated · median 3 years (range 2-5)As given in this study (human).

    Measurements

    Predicted adult height increase
    7.1 cm
    children with CAH on histrelin, ± 6.6

    Source sentences

    Summary
    Bone age (BA) to chronologic age (CA) decreased from 1.57 ± 0.4 to 1.25 ± 0.25 (P < .01), while predicted adult height (PAH) increased by 7.1 ± 6.6 cm (P < .01).
    3 context sentences
    Summary · context
    Fifteen children with CAH were treated with histrelin for a median of 3 years (range 2-5; age at first implantation 7.7 ± 1.5 years).
    Summary · context
    Retrospective cohort analysis of all patients (age ≤ 20) at our institution who underwent histrelin implantation between 2008 and 2017.
    Summary · context
    Treated patients with CAH (classic and nonclassic forms of 21OHD) were identified and their growth data analyzed.
  3. 03HumanObservational studyEfficacy outcome

    In the subgroup of 10 children with CAH who reached adult height, BA/CA changed similarly to the whole group, in which it decreased (P = .02).

    In plain wordsIn 10 children with CAH who reached adult height, bone age relative to chronological age fell, similar to all treated children.

    Peptide
    Histrelin
    Outcome
    DecreaseBone age ratio in adult-height subgroup
    Study

    n = 10

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similar changes in BA/CA and PAH were observed with therapy (P = .02).
    4 context sentences
    Summary · context
    A subgroup of 10 children reached adult height.
    Summary · context
    Bone age (BA) to chronologic age (CA) decreased from 1.57 ± 0.4 to 1.25 ± 0.25 (P < .01), while predicted adult height (PAH) increased by 7.1 ± 6.6 cm (P < .01).
    Summary · context
    Retrospective cohort analysis of all patients (age ≤ 20) at our institution who underwent histrelin implantation between 2008 and 2017.
    Summary · context
    Treated patients with CAH (classic and nonclassic forms of 21OHD) were identified and their growth data analyzed.
  4. 04HumanObservational studyEfficacy outcome

    In the subgroup of 10 children with CAH who reached adult height, predicted adult height changed similarly to the whole group, in which it increased (P = .02).

    In plain wordsIn 10 children with CAH who reached adult height, predicted adult height rose, similar to all treated children.

    Peptide
    Histrelin
    Outcome
    IncreasePredicted height in adult-height subgroup
    Study

    n = 10

    Outcome group
    Linear growth · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similar changes in BA/CA and PAH were observed with therapy (P = .02).
    4 context sentences
    Summary · context
    A subgroup of 10 children reached adult height.
    Summary · context
    Bone age (BA) to chronologic age (CA) decreased from 1.57 ± 0.4 to 1.25 ± 0.25 (P < .01), while predicted adult height (PAH) increased by 7.1 ± 6.6 cm (P < .01).
    Summary · context
    Retrospective cohort analysis of all patients (age ≤ 20) at our institution who underwent histrelin implantation between 2008 and 2017.
    Summary · context
    Treated patients with CAH (classic and nonclassic forms of 21OHD) were identified and their growth data analyzed.
  5. 05HumanObservational studyEfficacy outcome

    In children with CAH treated with histrelin, adult height z exceeded pretreatment PAH z (-1.42 ± 0.9 versus -1.96 ± 1.1, P < .01).

    In plain wordsIn children with CAH treated with histrelin, adult height exceeded the pretreatment prediction.

    Peptide
    Histrelin
    Outcome
    IncreaseAdult height z versus pretreatment prediction
    Study

    n = 10

    Comparator
    Pretreatment predicted adult height z
    Outcome group
    Linear growth · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Adult height z-score
    −1.42 z-score
    children with CAH who reached adult height, ± 0.9
    Pretreatment predicted adult height z-score
    −1.96 z-score
    same children, ± 1.1

    Source sentences

    Summary
    Adult height z improved compared to pretreatment PAH z (-1.42 ± 0.9 vs. -1.96 ± 1.1 respectively, P < .01), but remained lower than midparental height z (P = .01).
    3 context sentences
    Summary · context
    A subgroup of 10 children reached adult height.
    Summary · context
    Retrospective cohort analysis of all patients (age ≤ 20) at our institution who underwent histrelin implantation between 2008 and 2017.
    Summary · context
    Treated patients with CAH (classic and nonclassic forms of 21OHD) were identified and their growth data analyzed.
  6. 06HumanObservational studyEfficacy outcome

    In children with CAH treated with histrelin, adult height z remained below midparental height z (P = .01).

    In plain wordsIn children with CAH treated with histrelin, adult height remained below midparental height.

    Peptide
    Histrelin
    Outcome
    DecreaseAdult height z versus midparental height
    Study

    n = 10

    Comparator
    Midparental height z
    Outcome group
    Linear growth · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Adult height z improved compared to pretreatment PAH z (-1.42 ± 0.9 vs. -1.96 ± 1.1 respectively, P < .01), but remained lower than midparental height z (P = .01).
    3 context sentences
    Summary · context
    A subgroup of 10 children reached adult height.
    Summary · context
    Retrospective cohort analysis of all patients (age ≤ 20) at our institution who underwent histrelin implantation between 2008 and 2017.
    Summary · context
    Treated patients with CAH (classic and nonclassic forms of 21OHD) were identified and their growth data analyzed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.